Over recent weeks there has been renewed attention in the media and scientific literature on the APOE gene and its link with Alzheimer’s disease. What has drawn particular interest is not only the APOE4 variant, which has been discussed for many years, but growing recognition that APOE biology as a whole - including the very common APOE3 variant - may play a more central role in Alzheimer’s risk than previously thought. For many people, this raises an understandable question: should I be worried?

The most important place to begin is with reassurance. Genetic risk is not destiny. APOE does not cause Alzheimer’s disease. It influences vulnerability. Many people with APOE4 live cognitively healthy lives into old age, while some people without APOE4 develop dementia. This tells us something crucial: genes create a background sensitivity, but it is the environment, physiology, and nervous system that determine how - or whether - that risk is expressed.

The APOE gene encodes apolipoprotein E, a protein involved in lipid transport, membrane repair, immune signalling, and inflammation resolution. In the brain, this protein plays a key role in maintaining synapses, supporting blood–brain barrier integrity, and clearing metabolic waste products. When APOE function is less efficient, the brain may be slower to repair and more reactive to inflammatory and metabolic stress. Over time, this can contribute to processes associated with cognitive decline - particularly if other stressors are present.

This is why APOE is so closely linked to metabolic health. Blood sugar instability, insulin resistance, and altered lipid handling place additional strain on a brain that is already working harder to maintain balance. APOE-related vulnerability is often described as a “brain issue,” but in practice it is very often a whole-body metabolic issue that expresses itself neurologically over time.

Vascular health is equally important. The brain is an organ of blood flow, and subtle vascular compromise frequently precedes cognitive symptoms by many years. APOE variants influence how the brain responds to vascular stress and inflammation, which means that supporting circulation, endothelial health, and cardiovascular resilience is a cornerstone of prevention. Movement, strength, and aerobic capacity are not lifestyle extras here - they are biological interventions.

Inflammation is another central piece of the APOE story. APOE influences immune signalling and how effectively inflammation is resolved. Chronic low-grade inflammation, whether driven by gut-immune imbalance, metabolic strain, unresolved stress, poor sleep, or environmental load, accelerates cognitive ageing quietly and cumulatively. Prevention, in this context, is not about suppressing inflammation but about helping the body complete inflammatory cycles and return to regulation.

Sleep and nervous system regulation are often underestimated in Alzheimer’s prevention, yet they are fundamental. During deep sleep, the brain clears metabolic and inflammatory waste through the glymphatic system. When sleep is fragmented or the nervous system remains in a state of chronic vigilance, this clearance is impaired. APOE-related sensitivity often overlaps with heightened stress reactivity, which is why nervous system regulation, rhythm, and safety are central to my preventative work.

This is the context in which APOE genetic testing becomes useful. Testing is not about predicting disease. It is about identifying where prevention matters most. In my work, APOE testing is offered thoughtfully and interpreted alongside metabolic markers, inflammatory patterns, vascular indicators, sleep quality, nutrient status, and nervous system health. A result becomes meaningful only when it guides practical, personalised support rather than fear.

Prevention is not a single protocol or supplement. It is a layered, sustainable strategy that supports the biology of resilience over time. This includes stabilising blood sugar, nourishing brain lipids appropriately, reducing inflammatory burden, supporting circulation, optimising sleep, and regulating stress physiology. The goal is not control, but adaptability - helping the brain meet the demands of ageing with flexibility rather than fragility.

One of the most important aspects of this work is psychological containment. Genetic information can empower or destabilise depending on how it is held. APOE testing should never leave someone feeling doomed or hyper-vigilant about the future. My role is to help people understand their genetics without alarm, using insight to guide care rather than to predict decline. I test for this gene, among others, to keep you healthy and well.

The renewed focus on APOE in Alzheimer’s research does not mean we are waiting for a future drug to save us. It reinforces something far more hopeful: that Alzheimer’s risk is deeply influenced by modifiable biology. When genetics are used as a map rather than a sentence, prevention becomes calmer, earlier, and far more effective.

If you have a family history of dementia, are curious about APOE testing, or simply want to take a proactive approach to long-term brain health, this is work I can support you with. Together we look at the whole system - genetics, metabolism, inflammation, vascular health, sleep, and nervous system regulation - and build a personalised prevention strategy grounded in biology, not fear.

Brain health is not something we wait to lose and then try to recover. It is something we can support, protect, and strengthen long before symptoms appear. This is something I help people with, if you do or don't have those tricky genes. Let's get started.

I am right here…